Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(55.6%)

N/A

4(44.4%)

9Total

Phase 2(5)

N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06104098Not ApplicableCompleted

A User Study With Vernivia® for Bacterial Vaginosis.

Role: lead

NCT04489290Not ApplicableUnknown

Efficacy and Safety of D005 Vaginal Mousse on Bacterial Vaginosis

Role: lead

NCT05012852Not ApplicableUnknown

Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis

Role: lead

NCT04629885Phase 2Completed

Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms

Role: lead

NCT03998722Not ApplicableCompleted

Evaluation of VagiVital® for Treatment of Vaginal Atrophy

Role: lead

NCT01987804Phase 2Completed

Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women

Role: lead

NCT02497547Phase 2Completed

An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy

Role: lead

NCT01975129Phase 2Completed

A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin

Role: lead

NCT01432470Phase 2Completed

Study of Oxytocin to Treat Vaginal Atrophy in Postmenopausal Women

Role: lead

All 9 trials loaded